Mark P Burns Selected Research

Mark P Burns Research Topics

Disease

12	Alzheimer Disease (Alzheimer's Disease) 01/2019 - 01/2003
9	Traumatic Brain Injuries (Traumatic Brain Injury) 01/2020 - 09/2008
3	Brain Injuries (Brain Injury) 01/2023 - 12/2013
3	Neurodegenerative Diseases (Neurodegenerative Disease) 11/2016 - 09/2009
2	Cognitive Dysfunction 10/2021 - 04/2013
2	Neuroblastoma 03/2010 - 09/2009
2	Amyloid Plaque 09/2009 - 01/2003
1	Memory Disorders (Memory Loss) 01/2024
1	Seizures (Absence Seizure) 01/2023
1	Hyperalgesia 01/2017
1	Metabolic Brain Diseases (Encephalopathy, Metabolic) 01/2017
1	Neuroinflammatory Diseases 01/2017
1	Spinal Cord Injuries (Spinal Cord Injury) 04/2014
1	Wounds and Injuries (Trauma) 01/2014
1	Fragile X Syndrome (Martin Bell Syndrome) 01/2011
1	Dementia (Dementias) 09/2009
1	Inflammation (Inflammations) 03/2009

Drug/Important Bio-Agent (IBA)

6	CholesterolIBA 08/2010 - 01/2003
4	Amyloid (Amyloid Fibrils)IBA 03/2016 - 02/2011
4	Amyloid beta-PeptidesIBA 01/2014 - 08/2006
3	Apolipoprotein E4IBA 01/2018 - 04/2013
3	Amyloid Precursor Protein Secretases (beta-Secretase)IBA 04/2014 - 04/2009
3	Peptides (Polypeptides)IBA 12/2013 - 08/2006
2	salicylhydroxamic acid (SHAM)IBA 01/2024 - 01/2014
2	Messenger RNA (mRNA)IBA 01/2023 - 03/2010
2	Glucose (Dextrose)FDA LinkGeneric 01/2020 - 01/2017
2	Proteins (Proteins, Gene)FDA Link 01/2016 - 01/2016
2	ApolipoproteinsIBA 01/2016 - 01/2003
2	LipidsIBA 03/2010 - 09/2008
1	Glutamic Acid (Glutamate)FDA Link 01/2023
1	Amino Acid Transport System X-AG (Glutamate Transporter)IBA 01/2023
1	Ceftriaxone (Ceftriaxon)FDA LinkGeneric 01/2023
1	Pentylenetetrazole (Metrazol)IBA 01/2023
1	Memantine (Namenda)FDA Link 10/2021
1	Phosphotransferases (Kinase)IBA 01/2019
1	LigandsIBA 01/2017
1	CC ChemokinesIBA 01/2017
1	Chemotactic FactorsIBA 01/2017
1	NeurotoxinsIBA 01/2017
1	Insulin (Novolin)FDA Link 01/2017
1	ChemokinesIBA 01/2017
1	Neurotransmitter Agents (Neurotransmitter)IBA 01/2017
1	DNA (Deoxyribonucleic Acid)IBA 11/2016
1	RNA-Binding Proteins (RNA-Binding Protein)IBA 11/2016
1	Apolipoproteins E (ApoE)IBA 01/2016
1	EnzymesIBA 04/2014
1	N2- ((2S)- 2- (3,5- difluorophenyl)- 2- hydroxyethanoyl)- N1- ((7S)- 5- methyl- 6- oxo- 6,7- dihydro- 5H- dibenzo(b,d)azepin- 7- yl)- L- alaninamideIBA 12/2013
1	gaboxadol (THIP)IBA 01/2011
1	GABA-A Receptor AgonistsIBA 01/2011
1	Fatty Acid Synthases (Fatty Acid Synthase)IBA 03/2010
1	Fatty Acids (Saturated Fatty Acids)IBA 03/2010
1	Hydroxymethylglutaryl CoA Reductases (HMG CoA Reductase)IBA 03/2010
1	Acetyl-CoA CarboxylaseIBA 03/2010
1	Farnesyl-Diphosphate Farnesyltransferase (Squalene Synthase)IBA 03/2010
1	24-hydroxycholesterolIBA 03/2010
1	amyloid beta-protein (1-42)IBA 09/2009
1	LDL Receptors (LDL Receptor)IBA 03/2009
1	JNK Mitogen-Activated Protein KinasesIBA 03/2009
1	Tissue Inhibitor of Metalloproteinase-3IBA 10/2007

Therapy/Procedure

1	Treatment Delay 01/2023